Gilead Says FDA Expands Approval of Chronic Hep-B Infection Treatment for Use in Kids
By Will Feuer
Gilead Sciences said the Food and Drug Administration has approved the expanded use of Vemlidy, its treatment for chronic hepatitis B virus infection, in certain kids ages six and older.
Kids treated with the once-daily 25 mg tablet need to weigh at least 25 kg and have compensated liver disease, Gilead said.
Vemlidy was approved by the FDA in 2016 as a once-daily treatment for adults with chronic HBV infection with compensated liver disease. In 2022, the FDA expanded the approval to kids 12 and older.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
March 28, 2024 09:06 ET (13:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks